3,196
Participants
Start Date
July 11, 2016
Primary Completion Date
October 4, 2017
Study Completion Date
October 4, 2017
aH5N1c
Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
Placebo
Placebo: Saline injection
RCR/United Medical Associates, PC, Binghamton
Rochester Clinical Research, Inc, Rochester
Optimal Research, LLC, Rockville
PMG Research of Winston-Salem, Winston-Salem
Spartanburg Medical Research, Spartanburg
Medical Research South, Charleston
Optimal Research, LLC, Melbourne
Innovative Research of West Florida, Inc., Clearwater
Optimal Research, LLC, Huntsville
Aventiv Research, Columbus
Great Lakes Clinical Trials LLC, Chicago
PMG Research of Raleigh, Raleigh
Optimal Research, Peoria
Sundance Clinical Research, LLC, St Louis
The Center for Pharmaceutical Research, Kansas City
Heartland Research Associates, Wichita
Biogenics Research Institute, San Antonio
J. Lewis Research, Inc/Jordan River Family Medicine, South Jordan
J. Lewis Research Inc.-Foothill Family Clinic, Salt Lake City
J. Lewis Research, Inc. / FirstMed East, Salt Lake City
J. Lewis Research, Inc/Foothill Family Clinic South, Salt Lake City
Radiant Research, Chandler
Clinical Research Consortium Arizona, Tempe
Optimal Research Site, San Diego
California Research Foundation, San Diego
Clinical Research Consulting, LLC, Milford
Biomedical Advanced Research and Development Authority
FED
Seqirus
INDUSTRY